Increasingly, oncologists are turning to tumor mutation burden (TMB) as a biomarker of response to immune checkpoint inhibitors. However, recent research suggests that TMB needs to be further refined before it can be adopted broadly across tumor types and patient populations.

©2021 American Association for Cancer Research.
2021
American Association for Cancer Research.
You do not currently have access to this content.